Evidence map›Paper›PMID 35600024›Full record

ArticleClinical case reports2022

Perampanel markedly improved clinical seizures in a patient with a Rett-like phenotype and 960-kb deletion on chromosome 9q34.11 including the

Syun Yoshida, Masano Amamoto, Tomoyuki Takahashi, Ichiro Tomita, Kotaro Yuge, Munetsugu Hara, Kazuhiro Iwama, Naomichi Matsumoto, Toyojiro Matsuishi

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Syun YoshidaChildren's Medical Center Kitakyushu City Yahata Hospital Kitakyushu Japan.
Masano AmamotoChildren's Medical Center Kitakyushu City Yahata Hospital Kitakyushu Japan.
Tomoyuki TakahashiDivision of Gene Therapy and Regenerative Medicine Cognitive and Molecular Research Institute of Brain Diseases Kurume University School of Medicine Kurume Japan.
Ichiro TomitaChildren's Medical Center Kitakyushu City Yahata Hospital Kitakyushu Japan.
Kotaro YugeDepartment of Pediatrics and Child Health Kurume University School of Medicine Fukuoka Japan.
Munetsugu HaraDepartment of Pediatrics and Child Health Kurume University School of Medicine Fukuoka Japan.
Kazuhiro IwamaDepartment of Human Genetics Graduate School of Medicine Yokohama City University Kanagawa Japan.
Naomichi MatsumotoDepartment of Human Genetics Graduate School of Medicine Yokohama City University Kanagawa Japan.
Toyojiro MatsuishiDivision of Gene Therapy and Regenerative Medicine Cognitive and Molecular Research Institute of Brain Diseases Kurume University School of Medicine Kurume Japan.ORCID https://orcid.org/0000-0003-2635-0458
Kurume University · JPKitakyushu City Hospital Organization · JPYokohama City University · JP

Funding

Wellcome Trust FC001039
6 · The paper itself

Abstract

Intractable epilepsy was successfully controlled using perampanel, an α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-type glutamate receptor antagonist, in a 27-year-old woman who presented with a Rett syndrome-like phenotype and novel 960-kb deletion involving syntaxin-binding protein 1 on chromosome 9q34.11. Perampanel may be an effective antiepileptic drug for intractable epilepsy associated with

Indexed as

AMPA receptorintractable epilepsyperampanelRett‐like disorderSTXBP1 mutationWest syndrome

Identifiers

PMID35600024
PMCPMC9107918
OpenAlexW4280605520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.